Swedish Orphan Biovitrum AB (Sobi) is scrambling for its next move after a buyout by a private equity syndicate has fallen through, scuttling what – with a value of $8.1bn – would have been the sixth largest biopharma merger of 2021.
Sobi Loses Private Equity Buyout
An $8bn public-to-private takeout by two private equity firms of the Swedish rare disease specialist collapses because total tenders to the offer fell below a 90% threshold.
